HR+/HER2- T1-2 N1M0 breast cancer patients with tumor size >14mm and age older than 54 and cohort with tumor size >14mm and grade worse than well-differentiated could benefit from the PMRT. This evidence concerns the gene ERBB2 and neoplasm.